{"id":"W2990707530","doi":"10.1182/blood-2019-124407","title":"First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Venetoclax; Bortezomib; Tolerability; Internal medicine; Ven; Regimen; Oncology; Proteasome inhibitor; Lenalidomide; Dexamethasone; Carfilzomib; Combination therapy; Phases of clinical research; Multiple myeloma; Pharmacology; Clinical trial; Adverse effect; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003748307,0.001498508,0.00257546,0.0005586567,0.0006829808,0.001496691,0.0009197411,0.001307136,0.004916493],"category_scores_gemma":[0.002334965,0.0007342156,0.002813318,0.0006902806,0.0009800101,0.00104783,0.0005649802,0.002535242,0.0009422676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001538177,"about_ca_system_score_gemma":0.001982396,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00128029,"about_ca_topic_score_gemma":0.003180246,"domain_scores_codex":[0.9985051,0.0008164188,0.00008507384,0.0002459096,0.0001585363,0.0001889232],"domain_scores_gemma":[0.9977682,0.0004975128,0.0004487638,0.0002397491,0.000153506,0.0008922486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8378944,0.03939136,0.03320671,0.0009944619,0.006615163,0.000450746,0.0002936356,0.001308634,0.01893917,0.0001781104,0.004265425,0.05646223],"study_design_scores_gemma":[0.5006475,0.429531,0.05648347,0.00006683754,0.00384885,0.000638653,0.00009401241,0.0007679961,0.002394071,0.0001739575,0.005301145,0.00005261481],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846506,0.004392636,0.0008395906,0.000483889,0.0001081379,0.003602119,0.003904625,0.0001066954,0.001911695],"genre_scores_gemma":[0.9839065,0.001832414,0.002348693,0.001098879,0.0002616419,0.002291593,0.006499619,0.00005026461,0.001710393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004916493,"threshold_uncertainty_score":0.01982319,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0109241296040956,"score_gpt":0.2625402271636517,"score_spread":0.2516160975595561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}